-
Posted by
Two Blokes May 21 -
Filed in
Stock
-
3 views
Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, while maintaining solid margins and forward growth expectations. Risks include increased competition in the ATTR-CM market and ongoing technical downtrends, but cost-cutting measures may enhance efficiency.
